The publisher told us at the time it was looking into the matter carefully. In a May 9 email, however, Deborah Kendall-Cheeseman, a communications manager at Springer Nature, told us: Im afraid we dont have an update we can share at the moment but well let you know once we do
Thats in addition to its new GLP-1 treatment CagriSema, a combination of GLP-1 drug and a second drug geared towards diabetes and weight loss
Weight regain and unrealistic expectations These medications are not a permanent solution
For recipes, real-life tips, and GLP-1 weight loss stories, join the GLPbase.com forum and share your journey with the community
Following the success of the SELECT trial, Wegovy (semaglutide in doses of 1.7 mg and 2.4 mg) received a similar approval in March 2024 for people with overweight or obesity and cardiovascular disease
Other contributors include: Hormonal shifts : As calorie intake drops, hunger signals may increase while fullness cues decrease, making it harder to stick with the routine that initially worked